Researchers use optogenetics to produce pain relief by shutting off neurons with light

Brighter prospects for chronic pain

Montreal, Quebec, Canada (April 20, 2016) – The potential of light as a non-invasive, highly-focused alternative to pain medication was made more apparent thanks to research conducted by scientists at the Montreal Neurological Institute and Hospital of McGill University and the McGill University Health Centre. Researchers bred mice with a light-sensitive trait in peripheral neurons that were known to be responsible for pain transmission. The mice were genetically modified so that these neurons, called Nav 1.8+ nociceptors, express proteins called opsins, which react to light, a process known as optogenetics.

When these sensory neurons are exposed to yellow light, the opsins move ions across the membrane, reducing the level of bioelectric activity of the cells. This effectively shuts off the neurons, decreasing the mouse’s sensitivity to touch and heat.

"The opsins we added to these neurons were initially isolated from archaebacteria and sense yellow light," explains Professor Philippe Séguéla, a researcher at the Montreal Neurological Institute and Hospital and the article’s senior author. "When we transfer these to neurons, we can control their responses simply by illuminating the skin with innocuous yellow light."

Optogenetics is a growing field of research with a wide variety of applications. In this case the activity of pain-signaling neurons was reduced in a localized part of the mouse’s body, the hind paw, and the duration of the effect could easily be controlled by the amount of time the light was applied. The precision of this technique underlines potential advantages for use in humans.

Light therapy based on optogenetics would have the advantage of providing "on-demand" analgesia (pain relief) to patients who could control their pain by shining light on the sensitive part of the body.

Opiates are the most commonly used treatment for chronic pain today, but they are often used systemically and not directed to the specific region of the body affected by the pain. The duration of the opiate effects can be estimated, but without the same precision as a beam of light.

Further advances in neuroscience are necessary to apply this method of pain relief to humans. Séguéla says one possible way to make human neurons photosensitive would be through the use of a harmless virus that could temporarily deliver opsins to certain neurons without causing side effects.

According to a report in the Community Health Survey, 1 in 10 Canadians between the ages of 12 and 44, about 1.5 million in total, experienced chronic pain–pain lasting over a period of months or years. Chronic pain is associated with a number of different medical conditions including diabetes, arthritis, cancer, shingles, and sciatica, among others. Chronic pain reduces the sufferer’s ability to perform daily tasks and may lead to other health issues such as sleep disorders and depression.

"Chronic pain is an increasingly big problem clinically and for many years we’ve relied only on opiates," says Séguéla. "It’s hard to treat because of tolerance, making it necessary to increase dosages, which leads to serious side effects. Optogenetic therapy could be a highly effective way to relieve chronic pain while avoiding the side effects of traditional pain medication."

The research, published in the journal eNeuro , was made possible with the support of the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council, the Quebec Pain Research Network, and the Louise and Alan Edwards Foundation.


Montreal Neurological Institute and Hospital

The Montreal Neurological Institute and Hospital – The Neuro is a world-leading destination for brain research and advanced patient care. Since its founding in 1934 by renowned neurosurgeon Dr. Wilder Penfield, The Neuro has grown to be the largest specialized neuroscience research and clinical centre in Canada, and one of the largest in the world. The seamless integration of research, patient care, and training of the world’s top minds make The Neuro uniquely positioned to have a significant impact on the understanding and treatment of nervous system disorders. The Montreal Neurological Institute is a McGill University research and teaching institute. The Montreal Neurological Hospital is part of the Neuroscience Mission of the McGill University Health Centre. For more information, please visit http://www.theneuro.ca


McGill University , 20.04.2016 (tB).

MEDICAL NEWS

Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…
Starting the day off with chocolate could have unexpected benefits
Better mental health supports for nurses needed, study finds

SCHMERZ PAINCARE

Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…
Jedes vierte Kind wünscht bessere Schmerzbehandlung
Lebensqualität von Patienten in der dauerhaften Schmerztherapie mit Opioiden verbessern

DIABETES

Bundestag berät über DMP Adipositas: DDG begrüßt dies als Teil…
Mit der Smartwatch Insulinbildung steuern
Verbände fordern bessere Ausbildung und Honorierung von Pflegekräften für Menschen…
Minimalinvasive Geräte warnen ungenügend vor Unterzuckerung
Typ-1-Diabetes und Hashimoto-Thyreoiditis treten häufig gemeinsam auf

ERNÄHRUNG

Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen
Corona-Erkrankung: Fehl- und Mangelernährung sind unterschätze Risikofaktoren

ONKOLOGIE

Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!
Deutsch-dänisches Interreg-Projekt: Grenzübergreifende Fortbildungskurse in der onkologischen Pflege
Sotorasib: Neues Medikament macht Lungenkrebs-Patienten Hoffnung

MULTIPLE SKLEROSE

NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen
Verzögerte Verfügbarkeit von Ofatumumab (Kesimpta®)
Neuer Biomarker bei Multipler Sklerose ermöglicht frühe Risikoeinschätzung und gezielte…
Multiple Sklerose beginnt oft lange vor der Diagnose
Goldstandard für Versorgung bei Multipler Sklerose

PARKINSON

Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…
Gemeinsam gegen Parkinson: bessere Therapie durch multidisziplinäre Versorgung